Cardiovascular Effects of Glucagon in Man
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Because glucagon in animals has positive inotropic and chronotropic effects in the presence of beta-adrenergic blockade, catecholamine depletion or full digitalization, its cardiovascular effects in man were studied during diagnostic cardiac catheterization. In 11 patients 3 to 5 mg intravenously significantly increased cardiac index, mean arterial pressure, heart rate and maximum rate of left ventricular pressure development, but left ventricular end-diastolic pressure and systemic vascular resistance did not change significantly. Action after a single dose began in one to three, reached a maximum in five to seven and lasted for 10 to 15 minutes. In six patients given only 1 mg the only significant changes were increased cardiac index and decreased systemic vascular resistance. Glucagon benefits cardiac performance in man, and with its demonstrated action in the absence of catecholamines and in the presence of full digitalization, may be useful to treat acute heart failure.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Glucagon also has the ability to inhibit gastric motility29 and promote renal glomerular filtration30, with notable effects evident on the cardiovascular system to increase heart rate, cardiac contractility and cardiac output31 (Figure 1).”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [31]
Citations
Cites
Some Aspects of the Biological Role of Adenosine 3',5'-monophosphate (Cyclic AMP)
SUTHERLAND, E. W., ROBISON, G. A., & BUTCHER, R. W. (1968) · Circulation · doi:10.1161/01.cir.37.2.279 · Cited by 965
STUDIES ON THE PHARMACOLOGY OF GLUCAGON
Farah, A., & Tuttle, R. (1960) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)25785-8 · Cited by 262
GLICK, G., PARMLEY, W. W., WECHSLER, A. S., SONNENBLICK, E. H., Lewis, R. M., & McGill, R. D. (1968) · Circulation Research · doi:10.1161/01.res.22.6.789 · Cited by 248
Self-citationGlucagon Provocative Test for Pheochromocytoma
Lawrence, A. M. (1967) · Annals of Internal Medicine · doi:10.7326/0003-4819-66-6-1091 · Cited by 129
MYOCARDIAL METABOLIC AND CONTRACTILE RESPONSE TO GLUCAGON AND EPINEPHRINE.
Regan, T. J., Lehan, P. H., HENNEMAN, D. H., BEHAR, A., & Hellems, H. K. (1964) · PubMed · Cited by 84
EFFECTS OF GLUCAGON ON RENAL FUNCTION IN MAN*
Elrick, H., Huffman, E. R., HLAD, C. J., WIIIPPLE, N., Staub, A., Smith, A. E., & YEARWOOD-DRAYTON, V. (1958) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-18-8-813 · Cited by 69
Glucagon Treatment of Insulin Reactions
Elrick, H., Witten, T. A., & Arai, Y. (1958) · New England Journal of Medicine · doi:10.1056/nejm195803062581005 · Cited by 55
Mechanisms of Contraction of the Normal and Failing Heart
Braunwald, E., Ross, J., & Sonnenblick, E. H. (1967) · New England Journal of Medicine · doi:10.1056/nejm196710122771505 · Cited by 55
Self-citationChronotropic Action of Glucagon on the Sinus Node.
Whitehouse, F. W., & James, T. N. (1966) · Experimental Biology and Medicine · doi:10.3181/00379727-122-31261 · Cited by 54
Effect of Chronic Administration of Glucagon to Rats and Rabbits.
Root, M. A. (1954) · Experimental Biology and Medicine · doi:10.3181/00379727-87-21302 · Cited by 19
Research works printed but not linked: 3
- Sporn, 1956, Am. J. Physiol., 187, 634
- Regan, 1964, J. Lab. & Clin. Med., 63, 638
- Snedecor, G. W. Statistical Methods Applied to Experiments in Agriculture and Biology. Fourth edition. Ames, Iowa: Iowa State College Press, 1946.
Cited by
The New Biology and Pharmacology of Glucagon
Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419
Treatment of Refractory Heart Failure with Infusion of Nitroprusside
Guiha, N. H., Cohn, J. N., Mikulic, E., Franciosa, J. A., & Limas, C. J. (1974) · New England Journal of Medicine · doi:10.1056/nejm197409192911201 · Cited by 379
Pharmacology, Pathophysiology and Management of Calcium Channel Blocker and ??-Blocker Toxicity
DeWitt, C. R., & Waksman, J. C. (2004) · Toxicological Reviews · doi:10.2165/00139709-200423040-00003 · Cited by 249
Cardiac Function in Mice Lacking the Glucagon-Like Peptide-1 Receptor
Gros, R., You, X., Baggio, L. L., Kabir, M. G., Sadi, A. M., Mungrue, I. N., Parker, T. G., Huang, Q., Drucker, D. J., & Husain, M. (2003) · Endocrinology · doi:10.1210/en.2003-0007 · Cited by 193
Action and therapeutic potential of oxyntomodulin
Pocai, A. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2013.12.001 · Cited by 191
Metadata
- Authors
- Parmley, W. W., Glick, G., & Sonnenblick, E. H.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1968-07-04
- Volume
- 279
- Issue
- 1
- Pages
- 12-17
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2316057122
- Cited by
- 246
- References
- 11
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 10 · 2023: 4 · 2021: 5 · 2020: 2 · 2019: 4 · 2018: 5 · 2017: 2 · 2016: 5 · 2015: 2 · 2013: 2 · 2012: 1
- FWCI
- 48.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- glucagon, cardiovascular effects, cardiac index, mean arterial pressure, heart rate, systemic vascular resistance, left ventricular end-diastolic pressure, intravenous administration, acute heart failure, digitalization, beta-adrenergic blockade, catecholamine depletion
- MeSH terms
- Adolescent, Adult, Blood Glucose, Blood Pressure, Cardiac Output, Cardiovascular System, Digitalis Glycosides, Dye Dilution Technique, Electrocardiography, Female, Glucagon, Heart, Cardiac Catheterization, Heart Diseases, Heart Failure, Heart Rate, Hemodynamics, Humans, Injections, Intravenous, Middle Aged, Potassium, Vascular Resistance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cardiovascular Effects of Glucagon in Man. https://app.cochat.ai/papers/10.1056/nejm196807042790103
- The paper
- Parmley, W. W., Glick, G., & Sonnenblick, E. H. (1968). Cardiovascular Effects of Glucagon in Man. New England Journal of Medicine. https://doi.org/10.1056/nejm196807042790103
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.